MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.Read More
MyoKardia AHA Call (Replay)
November 12, 2018 at 8:00 a.m. ET
MyoKardia Inc at the Credit Suisse Healthcare Conference (Replay)
November 14, 2018 at 9:10 a.m. MT
Recent Press Releases
11/12/18MyoKardia Presents Preclinical Evidence of Mavacamten’s Novel Effect on Diastolic Compliance at the 2018 American Heart Association Scientific Sessions
NASDAQ GS | MYOK (Common Stock)
$54.07 - 2.52
10/26/184:00 p.m. ETData provided by Nasdaq. Minimum 15 minutes delayed.
There are currently no events scheduled.